Blood Tests for Colon Cancer Screening Risk Becoming Default Without Proper Guardrails
New ACS guidance allows blood-based colorectal cancer screening but critics warn the framework is too vague to prevent misuse.
Summary
The American Cancer Society now includes blood-based colorectal cancer (CRC) screening tests as an option for average-risk adults, but only as a fallback when preferred methods are declined. A leading gastroenterologist argues the guidance lacks the implementation framework needed to keep these tests from drifting into routine first-line use. Blood tests detect advanced precancerous lesions far less effectively than stool-based tests or colonoscopy, meaning widespread adoption could reduce the cancer-prevention benefits that make screening valuable in the first place. Without clear clinical protocols, EHR safeguards, and informed consent standards, convenience may override evidence — and patients could receive inferior screening without realizing it.
Detailed Summary
Colorectal cancer is one of the most preventable cancers when caught early, making the quality of screening decisions critically important for long-term health. The American Cancer Society's latest update introduces blood-based CRC screening tests as acceptable — though non-preferred — options for average-risk adults who decline or fail to complete established screening methods. While the intent is to boost overall screening uptake, a prominent critic argues the guidance creates more confusion than clarity.
The core problem is that once a test appears in major clinical guidelines, patients, payers, and clinicians frequently treat inclusion as endorsement. The distinction between 'listed as an option' and 'recommended equally' often collapses in practice. Blood-based tests have significantly lower sensitivity for advanced adenomas — precancerous lesions — compared to stool-based tests, and are dramatically inferior to colonoscopy. Since preventing cancer by catching precursor lesions is the primary goal of CRC screening, this gap is clinically meaningful, not merely technical.
The ACS acknowledges that blood-based tests are expected to reduce CRC incidence and mortality less effectively than established options. Yet the guidance stops short of providing the operational specifics needed to enforce their secondary role. There are no defined protocols for how many times preferred tests should be offered first, no recommended EHR order restrictions, and no structured informed consent language to help patients understand these are fallback tools.
In the absence of such a framework, convenience is likely to dominate. Blood draws are simpler than stool tests and far easier than colonoscopy. Clinicians under time pressure and health systems chasing screening metrics may default to blood tests prematurely, inadvertently reducing the preventive value delivered to patients.
For health-conscious adults, the practical implication is clear: colonoscopy or high-quality stool-based tests remain the gold standard. Blood-based CRC screening should be considered only after those options have genuinely been explored and declined.
Key Findings
- Blood-based CRC tests have far lower sensitivity for advanced precancerous lesions than stool tests or colonoscopy.
- ACS classifies blood tests as non-preferred but lacks protocols to prevent them becoming routine first-line screening.
- Guideline inclusion is often misread as equal endorsement by patients, clinicians, and payers.
- No EHR safeguards, consent frameworks, or outreach minimums are specified before blood tests can be offered.
- Colonoscopy and stool-based tests remain superior for actually preventing colorectal cancer, not just detecting it.
Methodology
This is an expert opinion piece published in MedPage Today's 'Second Opinions' section, authored by Aasma Shaukat, MD, MPH, a gastroenterologist with recognized expertise in CRC screening. It is commentary, not primary research, drawing on the ACS guideline update as its evidence basis. Credibility is high for perspective but lacks independent data.
Study Limitations
This article is editorial opinion, not a systematic review or clinical trial; conclusions reflect one expert's interpretation of the ACS update. The ACS guideline itself was not fully reproduced, so the full context of its recommendations cannot be independently verified here. Readers should consult the original ACS guidance and discuss screening options with their physician.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: